Document is current

Documents that mention this clinical trial

286 Sex differences in the transcriptional profiles of mucosal-associated invariant T cells in neoadjuvant anti-PD-1 treated non-small cell lung cancer (NSCLC)
https://doi.org/10.1136/jitc-2021-sitc2021.286

Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer
https://doi.org/10.1136/jitc-2020-001282

327 Development and validation of a neoantigen-specific T cell gene signature to identify antitumor T cells in lung cancer and melanoma
https://doi.org/10.1136/jitc-2021-sitc2021.327

1004 Immune checkpoint blockade unleashes mucosal associated invariant T (MAIT) cells in tumor microenvironment of NSCLC patients
https://doi.org/10.1136/jitc-2023-sitc2023.1004

293 Distinct tumor infiltrating treg lineages are associated with response to anti-PD1 checkpoint blockade in non-small cell lung cancer
https://doi.org/10.1136/jitc-2021-sitc2021.293

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma
https://doi.org/10.1136/jitc-2021-003956

538 Comprehensive single cell transcriptomic profiling of untreated resectable lung cancers
https://doi.org/10.1136/jitc-2022-sitc2022.0538

878 The immunomodulatory impact of chemotherapy when combined with PD-1 blockade in resectable lung cancers
https://doi.org/10.1136/jitc-2024-sitc2024.0878

Neoadjuvant immunotherapy for non-small cell lung cancer: right drugs, right patient, right time?
https://doi.org/10.1136/jitc-2020-002248

665 Transcriptional landscape of tumor-reactive TIL in lung cancer and melanoma
https://doi.org/10.1136/jitc-2021-sitc2021.665

57 CD8+FoxP3+ cells represent early, effector T-cells and predict outcomes in patients with resectable non-small cell lung carcinoma (NSCLC) receiving neoadjuvant anti-PD-1-based therapy
https://doi.org/10.1136/jitc-2022-sitc2022.0057

1255 Longitudinal assessment of the gut microbiome and its association with treatment response in patients with non-small cell lung cancer receiving neoadjuvant immunotherapy
https://doi.org/10.1136/jitc-2024-sitc2024.1255